Details for Patent: 8,492,386

Title:	Methods for treating HCV
Abstract:	The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Inventor(s):	Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Sep 04, 2012
Application Number:	13/603,006
Claims:	1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribaviron to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise: Compound 1 having formula of ##STR00011## or a pharmaceutically acceptable salt thereof, and Compound 4 having formula of ##STR00012## or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is co-administered with ritonavir. 2. The method of claim 1, wherein said patient is a treatment-naive patient. 3. The method of claim 1, wherein said at least two DAAs further comprise compound 2 having formula of ##STR00013## or a pharmaceutically acceptable salt thereof. 4. The method of claim 2, wherein said at least two DAAs further comprise compound 2 having formula of ##STR00014## or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein said patient is infected with HCV genotype 1a. 6. The method of claim 2, wherein said patient is infected with HCV genotype 1a. 7. The method of claim 3, wherein said patient is infected with HCV genotype 1a. 8. The method of claim 4, wherein said patient is infected with HCV genotype 1a. 9. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks. 10. The method of claim 9, wherein said patient is a treatment-naive patient. 11. The method of claim 9, wherein said patient is infected with HCV genotype 1a. 12. The method of claim 10, wherein said patient is infected with HCV genotype 1a. 13. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment as for 12 weeks. 14. The method of claim 13, wherein said patient is a treatment-naive patient. 15. The method of claim 13, wherein said patient is infected with HCV genotype 1a. 16. The method of claim 14, wherein said patient is infected with HCV genotype 1a.